Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15760261 | 0.81 | ACKR3 (0.35) | NUDT1ACKR3RIPK1 | |
| SCHEMBL20021215 | 0.75 | HTR2C (0.45) | NUDT1HTR2CACKR3 | |
| SCHEMBL7324694 | 0.70 | PIK3R1 (0.55) | HTR2CACKR3PIK3R1PIK3CA | |
| SCHEMBL15760262 | 0.70 | ACKR3 (0.39) | ACKR3RIPK1IGLV6-57MALT1 | |
| Hydrochloric Acid SCHEMBL4241072 | 0.68 | CHKA (0.50) | — | |
| Hydrochloric Acid SCHEMBL11172195 | 0.68 | HTR2C (0.61) | HTR2C | |
| SCHEMBL29893322 | 0.68 | HTR2C (0.44) | HTR2CPIK3R1PIK3CA | |
| SCHEMBL17697115 | 0.68 | CYP2D6 (0.48) | HTR2C | |
| SCHEMBL17206756 | 0.66 | ACKR3 (0.46) | ACKR3 | |
| SCHEMBL30753359 | 0.65 | HTR2C (0.47) | NUDT1HTR2CPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608839-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20240174695-A1 | Spirocycle Containing Bicyclic Heteroaryl Compounds | PROTEGO BIOPHARMA, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024092040-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174695-A1 | Spirocycle Containing Bicyclic Heteroaryl Compounds | BCL6, BCL6B, BCL9 | NUDT1 3941/4885HTR2C 2506/4885ACKR3 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.